MIMEDX GROUP, INC. – Trademark Portfolio
Entity Type: 03
MIMEDX GROUP, INC. holds 53 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 43 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 4 Nice Classification classes. Currently, 22 trademarks are registered and 4 are pending. Notable registered marks include NIVIS, EMERGE, EPIFIX, MIMEDX, and PURION. The owner is based in MARIETTA, GA.
1775 WEST OAK COMMON CT.
MARIETTA, GA 30062
Showing of trademarks Trademarks
Trademark Classifications
MIMEDX GROUP, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does MIMEDX GROUP, INC. have?
MIMEDX GROUP, INC. has 53 U.S. trademarks filed with the USPTO. Of these, 22 registered, 4 pending, 12 abandoned, 15 cancelled.
What trademark classes does MIMEDX GROUP, INC. file in?
MIMEDX GROUP, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 37 (Building & Construction). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are MIMEDX GROUP, INC.'s most well-known trademarks?
MIMEDX GROUP, INC.'s registered trademark portfolio includes well-known marks such as NIVIS, EMERGE, EPIFIX, MIMEDX, and PURION. These are among 22 currently registered trademarks in the portfolio.
What is MIMEDX GROUP, INC.'s trademark registration success rate?
MIMEDX GROUP, INC. has a 45% trademark registration rate, with 22 out of 49 resolved applications resulting in successful registration. Currently, 4 applications are pending review.